Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells 5,214 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Yakob Liawatidewi sold 5,214 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amphastar Pharmaceuticals Price Performance

AMPH stock traded up $2.22 during midday trading on Friday, reaching $48.31. 626,882 shares of the stock were exchanged, compared to its average volume of 397,490. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. The stock has a market capitalization of $2.35 billion, a PE ratio of 15.43, a P/E/G ratio of 0.97 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a fifty day moving average price of $48.45 and a 200 day moving average price of $44.13.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The business had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. As a group, analysts expect that Amphastar Pharmaceuticals, Inc. will post 3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $63.00.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the last quarter. Innealta Capital LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at about $55,000. Blue Trust Inc. increased its stake in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Asset Management One Co. Ltd. bought a new position in shares of Amphastar Pharmaceuticals during the third quarter worth about $78,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.